These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34575471)

  • 1. Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications.
    Adamiak-Giera U; Jawień W; Pierzchlińska A; Białecka M; Kobierski JD; Janus T; Gawrońska-Szklarz B
    Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection.
    Narożańska E; Białecka M; Adamiak-Giera U; Gawrońska-Szklarz B; Sołtan W; Schinwelski M; Robowski P; Madaliński MH; Sławek J
    Clin Neuropharmacol; 2014; 37(4):96-9. PubMed ID: 24992088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson's Disease.
    Conti V; Izzo V; Russillo MC; Picillo M; Amboni M; Scaglione CLM; Nicoletti A; Cani I; Cicero CE; De Bellis E; Charlier B; Giudice V; Somma G; Corbi G; Barone P; Filippelli A; Pellecchia MT
    Front Med (Lausanne); 2022; 9():909936. PubMed ID: 35712091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association.
    Benetello P; Furlanut M; Fortunato M; Pea F; Baraldo M
    Pharmacol Res; 1997 Apr; 35(4):313-5. PubMed ID: 9264047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
    Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
    Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine agonists: the treatment for Parkinson's disease in the XXI century?
    Lledó A
    Parkinsonism Relat Disord; 2000 Nov; 7(1):51-58. PubMed ID: 11008196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease--In relation to the effects of Mucuna pruriens.
    Nagashima Y; Kondo T; Sakata M; Koh J; Ito H
    J Neurol Sci; 2016 Feb; 361():229-34. PubMed ID: 26810548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.
    Cristina S; Zangaglia R; Mancini F; Martignoni E; Nappi G; Pacchetti C
    Clin Neuropharmacol; 2003; 26(3):146-50. PubMed ID: 12782917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
    Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
    J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methyl group-donating vitamins elevate 3-O-methyldopa in patients with Parkinson disease.
    Müller T; Jugel C; Muhlack S; Klostermann F
    Clin Neuropharmacol; 2013; 36(2):52-4. PubMed ID: 23503547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Systematic evaluation on influence of dopaminergic therapy: on motor complications in Parkinson's disease].
    Zhou MZ; Liu ZG; Chen W; Lu LX; Wu JY; Qi C
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):438-44. PubMed ID: 19567089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
    Müller T
    Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001517. PubMed ID: 11279719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.